Tom Wei‐Wu Chen

5.3k total citations · 1 hit paper
91 papers, 2.0k citations indexed

About

Tom Wei‐Wu Chen is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Tom Wei‐Wu Chen has authored 91 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 59 papers in Pulmonary and Respiratory Medicine, 56 papers in Oncology and 17 papers in Cancer Research. Recurrent topics in Tom Wei‐Wu Chen's work include Sarcoma Diagnosis and Treatment (25 papers), Cancer Immunotherapy and Biomarkers (13 papers) and Vascular Tumors and Angiosarcomas (11 papers). Tom Wei‐Wu Chen is often cited by papers focused on Sarcoma Diagnosis and Treatment (25 papers), Cancer Immunotherapy and Biomarkers (13 papers) and Vascular Tumors and Angiosarcomas (11 papers). Tom Wei‐Wu Chen collaborates with scholars based in Taiwan, China and Canada. Tom Wei‐Wu Chen's co-authors include Aaron R. Hansen, L.L. Siu, Daphne Day, Leila Khoja, Lillian L. Siu, Philippe L. Bédard, Ann‐Lii Cheng, A.R. Abdul Razak, Yen‐Shen Lu and Ching‐Hung Lin and has published in prestigious journals such as Nature Communications, The Journal of Experimental Medicine and Journal of Clinical Oncology.

In The Last Decade

Tom Wei‐Wu Chen

83 papers receiving 2.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review

2017 678 citations Tom Wei‐Wu Chen, Aaron R. Hansen et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Tom Wei‐Wu Chen Taiwan	19	1.4k	745	394	387	202	91	2.0k
Rohan Garje United States	17	1.1k 0.8×	556 0.7×	429 1.1×	422 1.1×	249 1.2×	79	1.8k
Leyre Zubiri United States	22	1.3k 0.9×	450 0.6×	402 1.0×	329 0.9×	287 1.4×	56	2.0k
Yusuke Okuma Japan	24	1.6k 1.1×	936 1.3×	549 1.4×	293 0.8×	273 1.4×	186	2.5k
Dusan Kotasek Australia	28	1.2k 0.8×	542 0.7×	448 1.1×	227 0.6×	282 1.4×	104	2.3k
Cinzia Solinas Italy	28	1.7k 1.2×	445 0.6×	421 1.1×	1.0k 2.6×	311 1.5×	80	2.4k
Nicholas E. Papadopoulos United States	28	1.4k 1.0×	706 0.9×	870 2.2×	484 1.3×	125 0.6×	82	2.4k
Filipe Martins Switzerland	8	1.4k 1.0×	403 0.5×	258 0.7×	510 1.3×	71 0.4×	13	1.8k
Kyung Hwan Kim South Korea	26	994 0.7×	485 0.7×	429 1.1×	509 1.3×	326 1.6×	95	2.2k
Ye Guo China	28	1.0k 0.7×	393 0.5×	684 1.7×	264 0.7×	336 1.7×	217	2.3k
Fengying Wu China	22	988 0.7×	906 1.2×	538 1.4×	178 0.5×	283 1.4×	97	1.8k

Countries citing papers authored by Tom Wei‐Wu Chen

Since Specialization

Citations

This map shows the geographic impact of Tom Wei‐Wu Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tom Wei‐Wu Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tom Wei‐Wu Chen more than expected).

Fields of papers citing papers by Tom Wei‐Wu Chen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tom Wei‐Wu Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tom Wei‐Wu Chen. The network helps show where Tom Wei‐Wu Chen may publish in the future.

Co-authorship network of co-authors of Tom Wei‐Wu Chen

This figure shows the co-authorship network connecting the top 25 collaborators of Tom Wei‐Wu Chen. A scholar is included among the top collaborators of Tom Wei‐Wu Chen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tom Wei‐Wu Chen. Tom Wei‐Wu Chen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wang, Xudong, Ying Guo, Tom Wei‐Wu Chen, et al.. (2025). Acyl post-translational modification of proteins by metabolites in cancer cells. Cell Death Discovery. 11(1). 247–247. 1 indexed citations

Guo, Ying, Xudong Wang, Chen Zhang, et al.. (2025). Tumor Immunotherapy Targeting B7-H3: From Mechanisms to Clinical Applications. ImmunoTargets and Therapy. Volume 14. 291–320. 7 indexed citations

Burns, Jessica, Tom Wei‐Wu Chen, Khin Thway, et al.. (2024). Proteomic features of soft tissue tumours in adolescents and young adults. SHILAP Revista de lepidopterología. 4(1). 93–93. 2 indexed citations

Lien, Huang‐Chun, Chia‐Lang Hsu, Yen‐Shen Lu, et al.. (2023). Transcriptomic alterations underlying metaplasia into specific metaplastic components in metaplastic breast carcinoma. Breast Cancer Research. 25(1). 11–11. 6 indexed citations

Wu, Chun‐Yu, Yen‐Heng Lin, Yucheng Huang, et al.. (2023). Delay of Surgery for Spinal Metastasis due to the COVID-19 Outbreak Affected Patient Outcomes. Neurospine. 20(4). 1431–1442. 4 indexed citations

Chen, Tom Wei‐Wu, Ming‐Shen Dai, Ching‐Hung Lin, et al.. (2023). Plasma cell-free tumor DNA, PIK3CA and TP53 mutations predicted inferior endocrine-based treatment outcome in endocrine receptor-positive metastatic breast cancer. Breast Cancer Research and Treatment. 201(3). 377–385. 5 indexed citations

Lin, Ching‐Hung, I‐Chun Chen, Ying‐Chun Shen, et al.. (2023). Disparity in survival benefits of pembrolizumab between Asian and non‐Asian patients with advanced cancers: A systematic review and meta‐regression analysis. Cancer Medicine. 12(19). 20035–20051. 1 indexed citations

Chen, Tom Wei‐Wu, Chia‐Lang Hsu, Ruey‐Long Hong, et al.. (2022). A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma. Clinical Cancer Research. 28(23). 5058–5065. 9 indexed citations

Chiu, Pei-Chen, Yunfei Chen, Tom Wei‐Wu Chen, et al.. (2022). XPF activates break-induced telomere synthesis. Nature Communications. 13(1). 5781–5781. 18 indexed citations

10.

Chen, Tom Wei‐Wu, A. Le Cesne, Antoîne Italiano, et al.. (2022). Soft tissue sarcoma incidences and clinical characteristics are significantly different in France and Taiwan. Cancer. 128(18). 3360–3369. 3 indexed citations

11.

Chen, Tom Wei‐Wu, Angela Pang, Mark E. Puhaindran, et al.. (2021). The treatment landscape of advanced angiosarcoma in Asia—A multi‐national collaboration from the Asian Sarcoma Consortium. Cancer Science. 112(3). 1095–1104. 10 indexed citations

12.

Chen, Tom Wei‐Wu, Jessica Burns, Robin L. Jones, & Paul H. Huang. (2020). Optimal Clinical Management and the Molecular Biology of Angiosarcomas. Cancers. 12(11). 3321–3321. 14 indexed citations

13.

Chen, Tom Wei‐Wu, et al.. (2020). When Molecular-Targeted Agents Meet Immunotherapy: The Opportunities for Soft Tissue Sarcoma. SHILAP Revista de lepidopterología. 3(2). 69–82. 2 indexed citations

14.

Lien, Huang‐Chun, et al.. (2020). Tumor-infiltrating lymphocyte abundance and programmed death-ligand 1 expression in metaplastic breast carcinoma: implications for distinct immune microenvironments in different metaplastic components. Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin. 478(4). 669–678. 17 indexed citations

15.

Li, Yiping, et al.. (2018). Primary Ewing Family of Tumor Arising in the Ovary: A Case Report. International Journal of Gynecological Pathology. 38(5). 470–473. 2 indexed citations

16.

Chen, Tom Wei‐Wu, Dah‐Cherng Yeh, Tsu‐Yi Chao, et al.. (2017). A Phase I/II study of the combination of lapatinib and oral vinorelbine in HER2-positive metastatic breast cancer. Japanese Journal of Clinical Oncology. 48(3). 242–247. 2 indexed citations

17.

Kuo, Hsiao-Hsuan & Tom Wei‐Wu Chen. (2016). [New Hope for HER2-Positive Metastatic Breast Cancer Treatment: Trastuzumab Emtansine (T-DM1) From the Perspective of Nursing Care].. PubMed. 63(5). 121–126. 3 indexed citations

18.

Lu, Yen‐Shen, Tom Wei‐Wu Chen, Ching‐Hung Lin, et al.. (2015). Bevacizumab Preconditioning Followed by Etoposide and Cisplatin Is Highly Effective in Treating Brain Metastases of Breast Cancer Progressing from Whole-Brain Radiotherapy. Clinical Cancer Research. 21(8). 1851–1858. 71 indexed citations

19.

Chen, Tom Wei‐Wu, A.R. Abdul Razak, Philippe L. Bédard, Lillian L. Siu, & Aaron R. Hansen. (2015). A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors. Annals of Oncology. 26(9). 1824–1829. 187 indexed citations

20.

Lin, Ching‐Hung, Chen‐Yang Shen, Jih‐Hsiang Lee, et al.. (2015). High Prevalence of the BIM Deletion Polymorphism in Young Female Breast Cancer in an East Asian Country. PLoS ONE. 10(4). e0124908–e0124908. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact